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We have generated transgenic mice containing hybrid llama
human antibody loci that contain two llama variable regions and
the human D, J, and C andor C constant regions. Such loci
rearrange productively and rescue B cell development efficiently
without LC rearrangement. Heavy-chain-only antibodies (HCAb)
are expressed at high levels, provided that the CH1 domain is
deleted from the constant regions. HCAb production does not
require an IgM stage for effective pre-B cell signaling. Antigen-
specific heavy-chain-only IgM or IgGs are produced upon immuni-
zation. The IgG is dimeric, whereas IgM is multimeric. The chimeric
HCAb loci are subject to allelic exclusion, but several copies of the
transgenic locus can be rearranged and expressed successfully on
the same allele in the same cell. Such cells are not subject to
negative selection. The mice produce a full antibody repertoire and
provide a previously undescribed avenue to produce specific hu-
man HCAb in the future.
immunoglobulin rearrangement  transgenic
Conventional antibodies contain two heavy and light chains (LC)coded for by heavy and LC loci. B cell development and
antibody production starts in the bonemarrow (BM) by heavy chain
(HC) VDJ recombination and expression of IgM associated with a
surrogate LC on the cell surface. In a second round of recombi-
nation, one of the LC rearranges in pre-B cells. If successful, the B
cells undergo selection, affinity maturation, and switching to dif-
ferent HC constant regions to result in B cells, which express
tetrameric antibodies of different isotypes (IgA, IgG, and IgE).
Normally absence of HC or LC expression leads to arrest of B cell
development. However, some species produce HC-only antibodies
(HCAb) as part of their normal B cell development and repertoire.
The best-knownHCAb (i.e., no LC) are IgG2 and IgG3 in camelids
(1). They undergo antigen-mediated selection and affinity matu-
ration, and their variable domains are subject to somatic hypermu-
tation (2, 3). HCAb are thought to recognize unusual epitopes, such
as clefts on the antigen surface (4). The first domain of the constant
region, CH1, is spliced out because of the loss of a consensus splice
signal (5, 6). CH1 exon loss also has been described in other
mammals, albeit associated with disease, e.g., in mouse myelomas
(7) and human HC disease (HCD) (8–10).
Camelid HCAbs contain a complete VDJ region. Its size, sta-
bility, specificity, and solubility have generated considerable bio-
technological interest. The antigen-binding site, a single-variable
domain (VHH), resembles VH of conventional Abs. However,
differences in FR2 and CDR3 prevent VHH to pair with a variable
LC, whereas hydrophilic amino acids provide solubility (11). HCAb
of the IgM class have not been found in camelids, suggesting that
the IgM stage of HCAb formation is very transient andor
circumvented.
Murine NSO myeloma cells can express a rearranged camelid
VHH-2a gene (12) and, recently, the same gene was expressed in
transgenic mice (13). Here, we describe transgenic mice containing
various nonrearranged chimeric HCAb loci and show they rear-
range properly, result in allelic exclusion, efficiently rescue B cell
development, and undergo class switch recombination and affinity
maturation. They generate functional HCAbs after antigenic chal-
lenge, providing a previously undescribed way of producing human
HCAb when the llama VHH regions are replaced with soluble
human VH.
Results
The CH1 Splice Mutation Is Insufficient for Exon Skipping in the Human
HC Locus. It is not known whether the generation of HCAb (IgG2
and 3) in camelids needs an IgM stage. Hence, we made two
hybrid chimeric loci, one locus (MGS) with human C, C, C2,
and C3 constant regions and one with only C2 and C3 (GS; Fig.
7, which is published as supporting information on the PNAS web
site) in a MT background (14). MT animals do not produce
surface IgM and have a block in B cell development at the pre-B
cell stage. The C regions first were mutagenized to contain the
camelidCH1 splicemutation (5).GSwas generated because of later
reports showing that MT mice produce some IgG, IgA, and IgE
in the absence of membrane IgM (15–17), suggesting some B cells
develop without IgM surface expression. Instead of mutating
humanVHdomains to improve solubility (18, 19), two llamaVHHs
were introduced. Camelid VHH contain characteristic amino acids
at positions 42, 49, 50, and 52 (20, 21). VHH1 contained these four,
but VHH2 had a Q instead of an E at 49. The locus contained all
of the human HC D and J regions and the locus control region
(LCR) (Fig. 7). Surprisingly, the splice mutation gave incorrect
CH1 exon skipping in mice and no chimeric Ig expression (Fig. 7).
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Fig. 1. The transgenic loci. Two llama VHH exons are linked to the human HC
diversity (D) and joining (J) regions, followed by the C, C, C2, and C3
human genes and human HC Ig 3 LCR. The different constant region exons are
shown in different colors (seeMiddle Right Inset). CH1 (red) was deleted from
C2 and C3 genes in constructs MG and G and also from C in construct
MG. LoxP sites (in red) enable removal of C and C genes by cre recom-
bination. The Frt site (in green) enables the generation of a single copy from
a multicopy array by Flp recombination.
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Chimeric Loci Lacking a Human CH1 Region. The CH1 splice problem
was solved by generating three new constructs (Fig. 1), all contain-
ing C2 and C3 with CH1 deleted, one with C and C (MG),
one without C and C (G), and one with CH1 deleted C
(MG). Three MG, six G, and four MG transgenic mouse
lines with one to five copies were obtained in a MT background.
Mice with different copy numbers gave the same results.
G and MG rescue B cell development. G and MG, but not
MG, rescued B cell development in a MT background. The
rescue of B220CD19 cells was between 30%and 100% in different
lymphoid compartments independent of copy number (Fig. 2A and
Table 1). The MG mice contain human IgM-producing cells in
the BM absent in WT or MT mice. Appropriately, they have not
switched class because chimeric IgG is absent. TheGmice contain
only chimeric IgGB cells. TheMGmice contain very few B cells
expressing cell-surface chimeric Ig, but interestingly, 30% of the
BMB220 cells express intracellular IgM, but not IgG (Fig. 2A). The
MG, but not theMG andG (data not shown), express mouse
Ig LC (see Fig. 5G). Thus, the C and C genes are expressed, and
absence of CH1 is crucial for surface-expressed HCAb.
HCAb replace mouse (pre-)BCR in the BM. During progression of large
cycling into small resting pre-B cells, specific surface markers are
down-regulated in a pre-BCR-dependent manner (22). To test
whether chimericHCAbs functionally replace the pre-BCR, various
markers were analyzed. Pro-B cells express high cytoplasmic SLC,
IL-7R and CD43, which are down-regulated upon pre-BCR ex-
pression and absent in mature B cells (Fig. 2B).
MGMT or GMT chimeric Ig B cells are SLC- and
Fig. 2. Flow cytometric analysis of B cells of wt, MT, MGMT, MGMT, and GMT mice in BM. (A) Lymphoid cells were gated on forward and side
scatter. Surface expression of B220 and chimeric IgM or IgG is shown as dot plots. For MGMT, the B220 fraction was gated and analyzed for the expression
of intracellular (ic) chimeric Ig  and H chains, displayed as histogram overlays (red lines), with background stainings of B220 cells from MT mice (black lines)
as controls. The % of positive cells is indicated. (B) MG or G transgenes rescue pre-BCR and BCR function. Shown are the expression profiles of the indicated
markers in total CD19 fractions fromMT mice (pro-B cells), in CD19 surface IgM fractions (pro-Bpre-B cells), and CD19 surface IgM fractions (B cells) from
WT, M-G MT, and G MT mice. ic-Ig , intracellular Ig  LC. Flow cytometric data are displayed as histograms representative of 3–8 animals examined in
each group. (C) Sequence alignment of BM cDNA showing VDJ recombination. Sequences are from G. Green shows sequence identity.
Table 1. Percent of B220CD19 cells in total population of
nucleated cells
Cell type WT G (5 copies) G (single copy) MG
BM 10.80  2.09 5.94  1.44 4.93  1.79 6.06  1.53
Spleen 41.80  6.05 32.14  9.46 28.70  8.70 33.95  3.24
Blood 43.72  7.50 16.00  5.68 16.01  3.76 9.25  3.24
Peritoneum 21.92  9.90 22.85  6.71* 22.30  7.29* 21.21  14.42
Mice were 14–20 weeks old. Numbers of mice analyzed are 5–11 per mouse
line with the exception of two peritoneal cell measurements, where calcula-
tions are based on two samples (marked by asterisks).









IL-7R-low, indicating that the chimeric HC IgG and IgM receptors
function as a pre-BCR in down-regulating SLC and IL-7R. CD43
persists in MG (not in G) mice, perhaps due to increased B-1
B cell differentiation. CD2 andMHC class II are induced normally.
The levels of the IL-2RCD25, transiently present in pre-B cells, are
very low onmatureMG or GMTB cells as inWT (Fig. 2B).
ic Ig was absent in mature MG or GMT B cells (Fig. 2B)
and was not induced in BM cultures upon IL-7 withdrawal after
IL-7 culture (data not shown). Finally, the chimeric HCAbB cell
populations in MG or G mice consisted of cells generated in
the BM (HSAhigh and AA4.1CD93high) and cells matured in the
periphery that are recirculating (HSAlow and CD93low) as in wild
type.
Thus, chimeric HCAb IgG and IgM function as (pre-)BCR with
respect to developmentally regulated markers. IgL chain is not
induced (see below). Both VHHs are used for VDJ recombination,
CH1 is absent and, importantly, CDR3 shows a large diversity
(Fig. 2C).
Multiple Rearrangements and Allelic Exclusion. MG and G
hybridomas were made after immunization. Particularly, the five-
copyG line1 could havemore than one rearrangement.Of the five
different five-copy hybridomas, one rearranged one in frame copy;
two hybridomas had two rearrangements, each with one out of
frame; one hybridoma had two in-frame rearrangements; and one
hybridoma had four rearrangements, with two in frame.
Two express two productive mRNAs (mass spectrometry con-
firmed the secreted HCAbs matching the cDNA; data not shown).
We also carried out DNA fiber FISH on a hybridoma with one
rearrangement and normal FISH on one with four rearrangements
by using an LCR probe detecting each copy and a probe between
VHH and D detecting only nonrearranged copies (Fig. 3 A–E).
Control cells showed five copies plus half a copy at each end (Fig.
3A), in agreement with Southern blots (data not shown), whereas
the hybridomas show one and four rearranged copies, respectively
(Fig. 3B–E). Thus,multiple copies can rearrange successfully on the
same allele.
Moreover B220CD19-positive BM cells of G line1 transgenic
mice in a WT background were analyzed for the expression of
transgenic IgG and mouse IgM. Clearly, the G B cells express
either mouse Ig or chimeric Ig (Fig. 3F), showing allelic exclusion.
Splenic B cells. Splenic B cell subpopulations were analyzed by using
CD21CD23 (Fig. 4A).GCD21lowCD23low immatureB cells were
Fig. 4. B cell populations in the spleen of WT, MT, G,
MG, and MGmice. Data shown are representative of 4–8
mice examined in each group. (A Upper) FACS data of spleen
cells, stained for mouse IgM, chimeric IgG, chimeric IgM versus
B220. (A Lower) Flow cytometric analysis of B cell populations
in spleen. Lymphoid cells were gated on forward and side
scatter. Surface expression of B220 and the indicated Ig
(A Upper) or the CD21CD23 profile is displayed as dot plots
and the % of cells within the indicated gates are given.
CD21lowCD23low, immature B cells; CD21CD23, follicular B
cells; CD21highCD23low, marginal zone B cells. (B) Histology of
the spleen of WT,MT, GMT, MGMT, and MGMT
mice. Immunohistochemical analysis is shown after 5-m fro-
zen sections were stained with B220 (blue) for B cells and
CD11cN418 (brown) for dendritic cells. Arrow indicates a
small cluster of B cells in MG spleen. (C) Sequence alignment
of Peyer’s patches cDNA showing that the transgenic locus
undergoes hypermutation in the CDR1 and 2 regions. Se-
quences are from the transgenic locus Gwith a CH1 deletion.
Fig. 3. DNA FISH and allelic exclusion of a five-copy chimeric G locus. (A)
Stretched chromatin fiber from lung cells of G line1 carrying five intact copies
(1–5) of the G locus, flanked by half of a locus containing the LCR (red) and
half of a locus containing VHH to J region (green). (B) Stretched chromatin
fiber FISH of a hybridoma (G20) derived from G line1 B cells where one copy
has rearranged (white arrow). (C) Nonstretched DNA FISH of hybridoma T1
with the LCR probe (red). (D) Same as C with a probe between VHH and D
(green). (E) Overlay of C and D. Note that T1 has four rearrangements visible
because of the loss of four green signals with no loss of red signals. (F) Allelic
exclusion in G mice. Flow cytometric analysis of murine surface or intracel-
lular (ic)H chain and chimeric IgG on total BM CD19 cells from G transgenic
mice in a WT background and a nontransgenic WT control mouse displayed as
dot plots. The % of cells within the quadrants is indicated. The average
extracellular and intracellular double expressors after subtraction of the
background were 1.5% and 5.8%, respectively (n  9).
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in normal ranges, and chimeric HC-IgG cells differentiated into
follicular (FO; CD21CD23) and marginal zone (MZ;
CD21highCD23low) B cells. In MG, the immature B cells were
increased, i.e., differentiation of HC-IgM expressing cells into FO
and MZ B cells appear somewhat impaired. CD23 reduction was
accompanied by increased CD43 and CD5 (data not shown),
indicative of differentiation into B-1 B cells. The few chimeric IgM
expressing B cells (also expressing mouse LC, see Fig. 5) in MG
mice had a FOMZ distribution similar to MG mice.
Spleen architecture in MG and G, but not MG mice, is
normal (Fig. 4B). As in wild type, germinal centers in B cell follicles
are formed (data not shown) during T cell-dependent responses
that in G mice contain chimeric IgG cells. We confirmed
hypermutation of theHCAb by cDNA analysis fromB cells present
in Peyer’s patches. (Fig. 4C). BothVHHs are used. Thus, inG and
MG mice, immature B cells migrating from BM differentiate
into spleen FOandMZBcells and undergo somatic hypermutation
upon antigen challenge.
Single-copy loci rescue efficiently and CH1 absence is essential. The G
line1 mice (Table 1) had five copies and, hence, the efficient rescue
was related possibly to the copy number of the locus. A single-copy
line generated from the G line1 through breeding with a FlpeR
line (23) gave the same B cell rescue (Table 1; Fig. 8, which is
published as supporting information on the PNAS web site).
Confirmation that a single copy of the locus is sufficient for
rescue and that a CH1 region is inhibitory was obtained by
cre-mediated deletion of the C andC fromMG line 3, resulting
in a single-copy G line (Fig. 8). This locus now rescues B cell
development like the other G lines. Thus, a CH1 region in C
inhibits B cell rescue, and copy number is not important.
Mouse Light Chains Do Not Rearrange in MG and GMice.Murine
LC were absent in the MG and Gmice byWestern blots (data
not shown, but see Fig. 2B and 5A) or FACS, suggesting that the
LC genes do not rearrange as confirmed by comparing the Ig locus
germ-line signals in sorted splenic B220 cells and liver DNA by
Southern blots (Fig. 9, which is published as supporting information
on the PNAS web site). Mouse LC remain in a germ-line config-
uration. In contrast, LC are present in the few chimeric Ig cells in
the MGMT mice (see Fig. 5G).
Thus, the chimeric HCAb expression in early B cell development
in BM fails to signal for LC rearrangement. In this respect, HCAb
lacking CH1 mimic a BCR rather than a pre-BCR, probably
because of a failure to bind pseudo-LC (24).
Serum analysis. Chimeric IgM was present in MG and chimeric
IgG in both MG and G serum. In nonimmunized adults, the
chimeric IgM (50gml) and IgG (200–1,000gml) are present
at levels comparable with those seen in WT or mice with a normal
human IgH locus (25). All six G mice had HCAb IgGs with a
molecularmass of80 kDaunder nonreducing and40 kDaunder
reducing conditions, consistent with HC dimers lacking a LC and
eachHC lacking CH1 (11 kDa shorter than the control human IgG;
Fig. 5 A and B).
The MG serum had multimeric HC-IgM. Under reducing
conditions (Fig. 5C), all four lines had IgMwith themolecular mass
of a human IgM after subtraction of CH1. Serum also was frac-
tionated (Fig. 5D, horizontal fractions) under nonreducing condi-
tions, and each fraction was analyzed under reducing conditions
(Fig. 5D, vertical lanes). When compared with the human pentam-
eric 900-kDa IgM, the transgenic IgM is 600 kDa, consistent with
amultimer lacking LC andCH1. Thus,MG orGmice produce
multimeric IgM andor dimeric IgG.
MGMice. Some clusteredB220-positive cells (1%of theWT) are
seen inMGMT spleens (Fig. 4B), and serum chimeric IgM and
IgGswere detected only after purification (Fig. 5E andF). The IgM
in thesemice was normal size, whereas the IgGs are shorter because
of CH1 deletion. Interestingly mouse LC, presumably associated
with the chimeric IgM, also were detected (Fig. 5G).
Immunization. The GMT mice were immunized with Esche-
richia coli hsp70, DKTP (Diphteria toxoid, whole cell lysate of
Bordetella pertussis, Tetanus toxoid, and inactivated poliovirus types
1–3), and rtTA (26), the MG mice with human TNF. Anti-
bodies were isolated from hybridomas or single-domain Ab (sdAb)
phage display libraries.
Sequencing (Fig. 6A) showed that both IgG2 (seven of eight) and
IgG3 [one of eight) were produced (the sdAb were isolated from a
IgG2 library]. Different D and J regions were used. When com-
paring all 14 antibodies, it was evident that all J regions are used,
but as in humans, JH4 is used most frequently. Surprisingly, all
antibodies had VHH2 (with a Q rather than E at position 49; ref.
20). Clearly CDR3 provides most diversity (27). It varies between
10 and 20 aa (average of 13.6 aa), as in llamas and humans (28, 29).
Although not at high frequency, theVHHwere hypermutated. The
3-hTNF antibodies (Fig. 5) had different hypermutations in the
CDR2 region.
The HCAb are functional in regular assays as hybridoma super-
natants and bacterial periplasmic fractions of sdAbs (Fig. 6). All
were positive in ELISAs and in antigen detection onWestern blots
(Fig. 6B). We also tested the -rtTA IgG in immunocytochemistry
in a rtTA cell line (Fig. 6C andD). The avidity of a number of the
antibodies was high, although some were low. For example, binding
studies of the -rtTA antibody used in the immunocytochemistry
Fig. 5. Prot G or concanavalin
purified serum samples of six dif-
ferent G lines (A and B), four
MG lines (C), and two MG
lines (E–G) in theMT background
run under nonreducing (A) and
reducing conditions (B–G). The
size of the chimeric IgG (B and F)
and IgM (C and D) is consistent
with a CH1 deletion and absence
of LC. Mouse  LC were normal
size (G). Human serum was used as
a positive control. (D) Superose 6
size fractionation of MG serum
after mixing in a human IgM con-
trol under nonreducing condi-
tions. Each fraction was analyzed
by gel electrophoresis under re-
ducing conditions. Fractions col-
lected of the column are from left (high MW) to right (low MW). Controls are human serum alone (first lane) and mouse serum before mixing in the human
IgM control serum (lane MG serum). Size markers are indicated.









(Fig. 6 C and D) by surface plasmon resonance analysis showed an
association rate kon of (2.1  0.002) 	 105 (M1s1) and a
dissociation rate koff of (4.1  0.02) 	 104 (s1) resulting in a
dissociation constant KD of 1.9 nM for anti-rtTA.
Discussion
Here, we reported that modified HCAb loci produce HCAb and
rescue B cell development in MTmice. Lack of CH1 is crucial for
HCAb secretion, but the camelid splice mutation at the 3 CH1
border (30) is insufficient for CH1 removal, thus more than this
point mutation is required, at least in the human-type locus.
VHH-IgM with CH1 blocks B cell development, probably because
of ineffective assembly of surface IgM as a pre-BCR. In contrast,
mice expressing aHCdisease-like human protein develop normal
CD43 pre-B cells in a SCID background independent of 5 (9).
Truncated IgM expressed on the B cell surface without L chains
mimics pre-BCR signaling through self-aggregation (10).
Normally BiP chaperones the folding and assembly of antibodies
by bindingCH1until it is replaced by (surrogate) LC (31).Although
VpreB1 and 2 can bind normal IgM in the absence of 5 (32), our
results suggest that transgenic  HC pairing with the Vpre protein
does not take place when a CH1-containing  HC is linked to a
VHH,which would lead to a failure of B cell development (33). The
MGS and MG transgenic mice containing a CH1 would be able
to form some pre-BCR-like complex that may lead to signaling,
causing some expansion and developmental progression and ex-
plain why 30% of the B220-positive cells in BM have intracellular
IgM (Fig. 2A). The fewmatured B cells in spleen of these micemay
be explained by the recently described novel receptor complex
lacking any SLC or LC (34).
When IgM is removed and C 2 and 3 lack CH1, there is rescue
of B cell development, showing that IgG can functionally replace
IgM. IgG1 expression from the pro-B cell stage onwards, was shown
to substitute for IgM inRag2/B cell development (35). Recently,
it also was shown that a prerearranged camelid IgG2a partially
rescues B cell development in one transgenic line in a MT (and a
C/) background (13). In our case, IgM or IgG lacking CH1
rescue B cell development in 10 of 10 independent lines. Moreover,
we see noLC rearrangement and conclude that LC are not required
for further B cell differentiation. The difference in our results and
those of Zou et al. (13) may be explained by the level of expression
of the locus (and, thus, signaling) because of the LCR on our
constructs. Our results confirm that truncated  HCAb lacking
CH1 (24) or VH and CH1 (36) cannot associate with SLCs and fail
to activate  gene rearrangement.
Interestingly, one or more HC rearrangements occur in multi-
copy loci (Fig. 3). Two of the hybridomas, originating from two
separate splenocytes gave two productive HCAb, confirming that
expression of two antibodies in oneB cell is not toxic (37).However,
the prediction (37) that they would loose in competition with single
antibody-producing cells under antigen challenge is not borne out
by finding two double antibody-expressing cells of five hybridomas.
The (multicopy) locus is subject to and exerts allelic exclusion in
WT background, because BM cells express either mouse or chi-
meric cell surface Ig. Few BM cells expressed both on the surface
(Fig. 3F). Interestingly, a five-copy GWT mouse has two mouse
alleles with one Ig locus each and one allele with five chimeric
HCAb loci. If alleles are chosen, there should be more mouse than
chimeric Ig expression, and if genes are chosen, there should be
more chimeric than mouse Ig expression. In fact, mouse Ig is
Fig. 6. Antibody properties. (A)
Sequences of monoclonal antibody
cDNAs specific for tetanus toxoid;
HSP70, rtTA, and human TNF. The
top sequence is the germ-line VHH2
sequence. The CDR 1, 2, and 3 and
hinge regions are indicated above
the sequence. Different isotypes
and classes are indicated by differ-
ent colors on the right. The J re-
gions that are used are indicated on
the right. (B) Examples of Western
blots by using the different HCAb
(hybridomas, sera, and sdAb). (B
Left) rtTA serum and hybridoma
medium, diluted 1100 and 1250.
(B Center) DKTP serum from WT
and G mice diluted 1200 and
1100. (B Right)  B. pertussis sdAb
against vaccine containing B. per-
tussis antigen (DKTP) or lacking it
(DTP, because we were unable to
purchase purified B. pertussis anti-
gen). (C and D) Immunostaining of
a Tet on cell line with a marker
plasmid responding to rtTA by ex-
pressing a marker in cytoplasm (44).
(C) Nuclei expressing rtTA (green).
(D) Doxycycline-induced expression
of the marker (red) in response to
rtTA and DAPI nuclear staining
(blue).
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expressedmore often (4438; Fig. 3F). Ignoring possible deviations
from the random V use and a possible position effect on the
transgenic locus, suggesting that the first choice is one of alleles.
Normally, a productive rearrangement down-regulates recombi-
nation to prevent rearrangement of the other allele. However, the
multiple transgenic copies, when rearranged, exclude the mouse
endogenous locus, but fail to exclude further rearrangement on the
same open locus before RAG down-regulation. This process may
involve a spatial component (‘‘compartment’’), in that the time
before the RAGs are down-regulated would be sufficient to rear-
range another gene in the locus because it would be in close
proximity. The observation that other species with multiple loci on
the same chromosome have more cells expressing two Abs (38)
supports this argument. Alternatively multiple rearrangements may
take place at the same time.
Importantly, we show that HCAb loci can be expressed success-
fully in mice. Antigen challenge results in antigen-specific chimeric
HCAb of different classes (dependent on locus composition)
expressed at levels comparable with WT or conventional human
IgH transgenicmice (25).Only twoVHHswere used, yet antibodies
with diverse specificity were isolated successfully to almost all of the
totally unrelated proteins we tested, demonstrating the efficiency
and efficacy of diversity generated by CDR3 (27). Thus, having
V(D)J recombination and in vivo selection provides an advantage
over antibodies of fragments thereof from synthetic libraries. Hy-
bridomas containing HCAb with a human effector function are
generated easily. They can be used also for direct cloning and
expression of sdAb, which can alternatively also be derived by phage
display.
Thus, these mice open up new possibilities to produce human
HCAb for clinical or other purposes, particularly in light of the
evidence (4) thatHCAbsmay recognize ‘‘difficult’’ epitopes such as
enzyme active sites. The restricted number of VHmay explain why
not all antigens were recognized; the polio and Diphteria proteins
gave no response in G mice, whereas WT control mice did (data
not shown). Surprisingly, all antibodies had VHH2 lacking a
conserved amino acid (39) at position 49 in contrast to VHH1 that
has one and should be more soluble. Perhaps, VHH1 expression
results in negative selection.
The addition of more VHs should lead to an even broader
repertoire.Whilst it is preferable to avoidmultiple copies on a single
allele, it would be advantageous to havemultiple alleleswith a single
copy of different VH regions to increase diversity. In such new loci,
one can use either normally occurring (human) VH or VH engi-
neered for increased solubility (18).
In conclusion, we show that antigen-specific HCAb of potentially
any class can be produced in mice. By introducing soluble human
VH domains in the locus, this technology allows the production of
fully human HCAb of any class or fragments thereof in response to
antigen challenge for use as therapeutic agents in man. By using
different vertebrate loci, our technology also allows for production
of antibodies from any vertebrate for use as reagents, diagnostics,
or for the treatment of animals.
Materials and Methods
A standard genomic cosmid library was made from Lama glama
blood. Two germ-line VHHs were chosen with hydrophilic amino
acid codons at positions 42, 50, and 52 according to ImMunoGe-
neTics numbering (40), one with and one without a hydrophilic
amino acid at 49. One is identical to IGHV1S1 (GenBank accession
no. AF305944), and the other has 94% identity with IGHV1S3
(GenBank accession no.AF305946). PAC clone 1065N8 contained
human HC D and J regions, C and C, and clone 1115 N15
contained C 3 (BACPAC Resource Center, Oakland, CA). Bac
clone 11771 (Incyte Genomics, Palo Alto, CA) was used to obtain
C2 and theHC-LCR(41). C3 andC2were subcloned separately
into pFastBac (Invitrogen, Carlsbad, CA). The point mutation (G
to A) (5) or deletion of CH1 was done by recombination (42).
Similarly, frt and lox P sites were introduced 5 to the C switch
region, and a second lox P site was placed 5 to the C2 switch
region, resulting in MGS or MG.
GS or G were generated from MGS or MG (Figs. 1 and
7) by cre recombination (43). MG was obtained from MG
by deletion of the C CH1 region through homologous
recombination. The generation of transgenic mice, breeding,
and genotyping, RT-PCR, f low cytometry, Ig gene arrange-
ment, DNA FISH analysis, immunization and hybridoma
production, sdAB library production and screening, immuno-
cytochemistry, Western blots, gel filtration, and BIAcore
measurements are described in Supporting Methods, which is
published as supporting information on the PNAS web site.
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